Ownership history in UBS Group AG · 4 quarters on record
This page tracks every 13F SEC filing in which UBS Group AG reported a position in ESTRELLA IMMUNOPHARMA INC (ESLAW). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | REDUCED | 1,285 | -47 | -3.5% | 0.00% | $67 | — |
| 2025 Q2 | REDUCED | 1,332 | -3,121 | -70.1% | 0.00% | $47 | — |
| 2025 Q1 | REDUCED | 4,453 | -637 | -12.5% | 0.00% | $343 | — |
| 2024 Q2 | INITIATED | 5,090 | — | — | 0.00% | $183 | — |
As of 2025 Q4 — sorted by position size